Centessa Pharmaceuticals plc Operating Income Loss

• Centessa Pharmaceuticals plc showed a decrease of -3.3% in Operating Income Loss from 2024 to 2025.
• This data is from Centessa Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2019 to 2025), Centessa Pharmaceuticals plc's Operating Income Loss has declined by 4,010.3%.
• Historical annual values: Fiscal year 2025: -$207.69 million | Fiscal year 2024: -$201.06 million | Fiscal year 2023: -$171.28 million | Fiscal year 2022: -$212.26 million | Fiscal year 2021: -$374.08 million | Fiscal year 2021: -$783.0 thousand | Fiscal year 2020: -$10.44 million | Fiscal year 2019: -$5.05 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026